NCT03249727 (ANKA-HR) is a NA clinical trial of IVDD for NK cell activity in whole blood in Immunity, Innate, sponsored by ATGen Canada Inc.

Who is sponsoring NCT03249727?

NCT03249727 is sponsored by ATGen Canada Inc.

What drugs are being tested in NCT03249727?

Interventions in NCT03249727: IVDD for NK cell activity in whole blood.

What condition does NCT03249727 study?

NCT03249727 studies Immunity, Innate, Colorectal Cancer.

Is NCT03249727 still recruiting?

NCT03249727 is currently terminated. Last updated 31 January 2023.

Last reviewed 2023-01-31 · How we verify

NCT03249727: ANKA-HR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Analysis of Natural Killer Cell Activity (NKA) in Whole Blood in High Risk Subjects Undergoing Colonoscopy

Terminated NA Last updated 31 January 2023

What this trial tests

NA trial testing IVDD for NK cell activity in whole blood in Immunity, Innate in 396 participants. Terminated before completion.

Timeline

5 July 2017

Primary endpoint
11 October 2018

11 October 2018

Quick facts

Lead sponsor	ATGen Canada Inc
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	single
Primary purpose	screening
Enrollment	396
Start date	5 July 2017
Primary completion	11 October 2018
Estimated completion	11 October 2018
Sites	3 locations across Canada

Drugs / interventions tested

IVDD for NK cell activity in whole blood

Conditions studied

Immunity, Innate — all drugs for Immunity, Innate →
Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

ATGen Canada Inc

Who can join

40 and older, any sex, with Immunity, Innate or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will measure the activity of natural killer (NK) cells using the in vitro diagnostic device NK Vue in high risk subjects (Quebec risk categories P2, P3 and P4) scheduled for colonoscopy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of IVDD for NK cell activity in whole blood

Trials testing the same drug.

NCT03242265 — Measurement of Natural Killer Cell Activity in Whole Blood in Men Being Screened for Prostate Cancer With Biopsy · NA · terminated

Other ATGen Canada Inc trials

Trials by the same sponsor.

NCT03242265 — Measurement of Natural Killer Cell Activity in Whole Blood in Men Being Screened for Prostate Cancer With Biopsy · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03249727 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ATGen Canada Inc
Last refreshed: 31 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03249727.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing